TY - JOUR
T1 - Benign Bone Conditions That May Be FDG-avid and Mimic Malignancy
AU - Kwee, Thomas C.
AU - de Klerk, John M. H.
AU - Nix, Maarten
AU - Heggelman, Ben G. F.
AU - Dubois, Stefan V.
AU - Adams, Hugo J. A.
PY - 2017/7
Y1 - 2017/7
N2 - Positron emission tomography with the radiotracer F-18-fluoro-2-deoxy-D-glucose (FDG) plays an important role in the evaluation of bone pathology. However, FDG is not a cancer-specific agent, and knowledge of the differential diagnosis of benign FDG-avid bone alterations that may resemble malignancy is important for correct patient management, including the avoidance of unnecessary additional invasive tests such as bone biopsy. This review summarizes and illustrates the spectrum of benign bone conditions that may be FDG-avid and mimic malignancy, including osteomyelitis, bone lesions due to benign systemic diseases (Brown tumor, Erdheim-Chester disease, Gaucher disease, gout and other types of arthritis, Langerhans cell histiocytosis, and sarcoidosis), benign primary bone lesions (bone cysts, chondroblastoma, chondromyxoid fibroma, desmoplastic fibroma, enchondroma, giant cell tumor and granuloma, hemangioma, nonossifying fibroma, and osteoid osteoma and osteoblastoma), and a group of miscellaneous benign bone conditions (post bone marrow biopsy or harvest status, bone marrow hyperplasia, fibrous dysplasia, fractures, osteonecrosis, Paget disease of bone, particle disease, and Schmorl nodes). Several ancillary clinical and imaging findings may be helpful in discriminating benign from malignant FDGavid bone lesions. However, this distinction is sometimes difficult or even impossible, and tissue acquisition will be required to establish the final diagnosis. (C) 2017 Elsevier Inc. All rights reserved.
AB - Positron emission tomography with the radiotracer F-18-fluoro-2-deoxy-D-glucose (FDG) plays an important role in the evaluation of bone pathology. However, FDG is not a cancer-specific agent, and knowledge of the differential diagnosis of benign FDG-avid bone alterations that may resemble malignancy is important for correct patient management, including the avoidance of unnecessary additional invasive tests such as bone biopsy. This review summarizes and illustrates the spectrum of benign bone conditions that may be FDG-avid and mimic malignancy, including osteomyelitis, bone lesions due to benign systemic diseases (Brown tumor, Erdheim-Chester disease, Gaucher disease, gout and other types of arthritis, Langerhans cell histiocytosis, and sarcoidosis), benign primary bone lesions (bone cysts, chondroblastoma, chondromyxoid fibroma, desmoplastic fibroma, enchondroma, giant cell tumor and granuloma, hemangioma, nonossifying fibroma, and osteoid osteoma and osteoblastoma), and a group of miscellaneous benign bone conditions (post bone marrow biopsy or harvest status, bone marrow hyperplasia, fibrous dysplasia, fractures, osteonecrosis, Paget disease of bone, particle disease, and Schmorl nodes). Several ancillary clinical and imaging findings may be helpful in discriminating benign from malignant FDGavid bone lesions. However, this distinction is sometimes difficult or even impossible, and tissue acquisition will be required to establish the final diagnosis. (C) 2017 Elsevier Inc. All rights reserved.
KW - POSITRON-EMISSION-TOMOGRAPHY
KW - LANGERHANS CELL HISTIOCYTOSIS
KW - RADIOLOGIC-PATHOLOGICAL CORRELATION
KW - ERDHEIM-CHESTER DISEASE
KW - DESMOPLASTIC FIBROMA
KW - CHONDROMYXOID FIBROMA
KW - F-18-FDG PET/CT
KW - DIFFERENTIAL-DIAGNOSIS
KW - METASTATIC-DISEASE
KW - OSTEOID OSTEOMA
U2 - 10.1053/j.semnuclmed.2017.02.004
DO - 10.1053/j.semnuclmed.2017.02.004
M3 - Review article
SN - 0001-2998
VL - 47
SP - 322
EP - 351
JO - Seminars in Nuclear Medicine
JF - Seminars in Nuclear Medicine
IS - 4
ER -